PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 7:01 AM ET

Sponsor Check › Person

PM
No photo found yet (own website and image search run after this page is viewed)

Peter Moldt

Named as an officer, director or promoter on SEC Form D filings · WA, CA, Denmark (as filed: G7), MO · Dec 20, 2012 → Sep 9, 2021

11deals (issuers)
$879.4Mreported sold
292investors
27Form D filings
2012–2021years on file

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:27 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Peter Moldt is listed as a director on 27 SEC Form D filings by 11 issuers between Dec 2011 and Oct 2023. Largest by amount reported sold: Avalyn Pharma Inc. (Seattle, WA — biotechnology — 2023; $189.2M reported sold to 46 investors), Aligos Therapeutics, Inc. (South San Francisco, CA — biotechnology — 2020; $105M reported sold to 38 investors), Swift Health Systems Inc. (Irvine, CA — other health care — 2019–2021; $102M reported sold to 26 investors), Allakos Inc. (San Carlos, CA — biotechnology — 2012–2015; $100.1M reported sold to 40 investors), Bolt Biotherapeutics, Inc. (Redwood City, CA — biotechnology — 2016–2021; $93.5M reported sold to 17 investors) and 6 more (all listed below).

What this means That is a lot of deals — 11 separate companies raised money with this person listed as director, over about 12 years. Across those companies the filings report $879.4M sold in total.

Listed alongside Peter A. Thompson (6 shared filings), Asish Xavier (5 shared filings), Bruce Montgomery (5 shared filings, management entity), Edgar Engleman (5 shared filings), John P. McKearn (5 shared filings) and 87 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Peter. Each name links to their own page.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 27 public filings for Peter Moldt and found 18 differences, 2 worth asking the sponsor about: Investor count went down between filings; 100% of the money raised went to insiders; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Peter Moldt has not run yet — it is joining a line of 21,979 names; searches run around the clock at the hosts' allowed rate. Searched so far: 363 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:27 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Peter Moldt..

State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

Moldt v. US Bank NA closed
United States Bankruptcy Court, W.D. Washington · No. 13-04262 · Filed Jun 12, 2013 · Closed Nov 12, 2013
Role of Moldt: Plaintiff · Outcome: Case closed 2013-11-12 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same rare surname (2 people in Form D filings, 2 federal dockets); surname only in the caption; court in the person's filing state (WA)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:27 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

18 differences found between the filings for Peter Moldt — 2 worth asking about (compared 27 filings on Oct 24, 2026)

Note · Jun 12, 2013 – Nov 12, 2013

Bankruptcy case: Moldt v. US Bank NA — filed Jun 12, 2013

United States Bankruptcy Court, W.D. Washington docket "Moldt v. US Bank NA" filed Jun 12, 2013, closed Nov 12, 2013. Peter Moldt is listed as Plaintiff ("Moldt"). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Sources
Note · May 13, 2005 – Jun 15, 2007

Bankruptcy case: Michael Bruce Montgomery — filed May 13, 2005

United States Bankruptcy Court, N.D. Florida docket "Michael Bruce Montgomery" filed May 13, 2005, closed Jun 15, 2007. Bruce Montgomery (listed on the same filings) is listed as Party ("Michael Bruce Montgomery").

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Sources
Note · Feb 21, 2005 – May 31, 2005

Bankruptcy case: Michael Bruce Montgomery and Claudia B. Montgomery — filed Feb 21, 2005

United States Bankruptcy Court, W.D. Texas docket "Michael Bruce Montgomery and Claudia B. Montgomery" filed Feb 21, 2005, closed May 31, 2005. Bruce Montgomery (listed on the same filings) is listed as Party ("Michael Bruce Montgomery and Claudia B. Montgomery").

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Sources
Worth asking · Jun 2, 2017 – Oct 11, 2018

Investor count went down between filings — ESCAPE Bio, Inc.

The Jun 2, 2017 filing reports 32 investors; the Oct 11, 2018 Form D/A reports 31 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Sources
Worth asking · Jul 12, 2019

100% of the money raised went to insiders — Swift Health Systems Inc.

The Jul 12, 2019 Form D reports $44,999,995 sold and $44,999,995 of the proceeds used for payments to officers, directors or promoters.

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Sources
Note · Aug 17, 2016

Peter Moldt appears on 1 deal that stopped filing before reaching its target

Tioma Therapeutics, Inc. (last filing Aug 17, 2016; $33,176,948 sold of $86,253,438). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Sources
Note · Sep 22, 2023 – Oct 10, 2023

Form D filed 18 days after the first sale — Avalyn Pharma Inc.

The filing says the first sale was Sep 22, 2023. The Form D was filed Oct 10, 2023 — 18 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 3 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Note · Dec 23, 2019 – Jan 16, 2020

Form D filed 24 days after the first sale — Aligos Therapeutics, Inc.

The filing says the first sale was Dec 23, 2019. The Form D was filed Jan 16, 2020 — 24 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 9 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Note · Jun 25, 2015 – Aug 7, 2015

Form D filed 43 days after the first sale — Tioma Therapeutics, Inc.

The filing says the first sale was Jun 25, 2015. The Form D was filed Aug 7, 2015 — 43 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 28 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Note · Dec 19, 2011 – Sep 9, 2021

8 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Swift Health Systems Inc. (latest filing Sep 9, 2021) · No amendment in the last 12 months on an offering that may still be open — Aligos Therapeutics, Inc. (latest filing Jan 16, 2020) · No amendment in the last 12 months on an offering that may still be open — ESCAPE Bio, Inc. (latest filing Jul 29, 2019) · No amendment in the last 12 months on an offering that may still be open — ViewPoint Therapeutics, Inc. (latest filing Mar 15, 2018) · No amendment in the last 12 months on an offering that may still be open — Bolt Biotherapeutics, Inc. (latest filing Sep 30, 2016) · and 3 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Sources
Note · Dec 30, 2011 – Oct 11, 2018

8 offerings changed their target amount between filings

Offering amount changed between filings — ESCAPE Bio, Inc. · Offering amount changed between filings — ESCAPE Bio, Inc. · Offering amount changed between filings — Tioma Therapeutics, Inc. · Offering amount changed between filings — CARDEAS PHARMA Corp · Offering amount changed between filings — Allakos Inc. · and 3 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Sources
Note · Aug 7, 2015 – Aug 17, 2016

Minimum investment changed between filings — Tioma Therapeutics, Inc.

The Aug 7, 2015 filing lists a minimum of $50,000; the Aug 17, 2016 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Sources
Note · Sep 30, 2016 – Jul 15, 2019

Industry group changed between filings — Bolt Biotherapeutics, Inc.

"Biotechnology" (Sep 30, 2016 to Feb 20, 2018); then "Other" (Aug 6, 2018); then "Biotechnology" (Jul 15, 2019 to Jun 7, 2021).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Sources
Note · Aug 31, 2015 – Oct 11, 2018

Industry group changed between filings — ESCAPE Bio, Inc.

"Other Health Care" (Aug 31, 2015 to Jun 2, 2017); then "Biotechnology" (Oct 11, 2018 to Sep 28, 2020).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Sources
Note · Aug 31, 2015

Formed in 2020 per the latest filing, but activity is dated 2015 — ESCAPE Bio, Inc.

The issuer's latest filing says it was formed in 2020. The Aug 31, 2015 filing says the first sale was Aug 19, 2015 — before that year.

What this means A company cannot sell before it exists, so one of the two dates is likely a typo on the form. Ask the sponsor for the formation document.

Sources
Note · Oct 12, 2018

Same name, different state: "Peter Moldt" (IN) is a separate record

This page covers filings where the address state is WA or CA or G7 or MO. A separate record, "Peter Moldt" with address state IN, is listed on 1 filing — most recently by Outpost Medicine, LLC (Oct 12, 2018). Both records have filings in the same period (Oct 12, 2018).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Sources
Note · Dec 20, 2012 – Sep 28, 2020

6 address changes between filings

Address moved from San Francisco, CA to South San Francisco, CA — ESCAPE Bio, Inc. · Address moved from South San Francisco, CA to San Francisco, CA — ESCAPE Bio, Inc. · Address moved from San Francisco, CA to South San Francisco, CA — ESCAPE Bio, Inc. · Address moved from Pleasanton, CA to Redwood City, CA — Bolt Biotherapeutics, Inc. · Address moved from Saint Louis, MO to Brisbane, CA — Tioma Therapeutics, Inc. · and 1 more

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Sources
Note · Dec 30, 2011 – Oct 10, 2023

Peter Moldt is listed with 4 different address states: WA, CA, MO, G7

WA on 6 filings (Dec 30, 2011 to Oct 10, 2023); CA on 19 filings (Dec 20, 2012 to Sep 9, 2021); MO on 1 filing (Aug 7, 2015); Denmark (as filed: G7) on 1 filing (Sep 25, 2015).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

0 of 19 offerings report sales commissions; 0 report finder's fees; 1 reports proceeds to related persons totalling $44,999,995. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Oct 10, 2023 D
Avalyn Pharma Inc.
File 021-494182
$0$0$0None listed on this filingEDGAR ↗
Sep 9, 2021 D
Swift Health Systems Inc.
File 021-412810
$0$0$0None listed on this filingEDGAR ↗
Jun 7, 2021 D
Bolt Biotherapeutics, Inc.
File 021-402021
$0$0$0None listed on this filingEDGAR ↗
Sep 28, 2020 D
ESCAPE Bio, Inc.
File 021-376482
$0$0$0None listed on this filingEDGAR ↗
Jan 16, 2020 D
Aligos Therapeutics, Inc.
File 021-358226
$0$0$0None listed on this filingEDGAR ↗
Jul 29, 2019 D
ESCAPE Bio, Inc.
File 021-345261
$0$0$0None listed on this filingEDGAR ↗
Jul 15, 2019 D
Bolt Biotherapeutics, Inc.
File 021-344279
$0$0$0None listed on this filingEDGAR ↗
Jul 12, 2019 D
Swift Health Systems Inc.
File 021-344163
$0$0$44,999,995None listed on this filingEDGAR ↗
Oct 11, 2018 D/A
ESCAPE Bio, Inc.
File 021-246718
$0$0$0 (est.)None listed on this filingEDGAR ↗
Aug 6, 2018 D
Bolt Biotherapeutics, Inc.
File 021-318563
$0$0$0None listed on this filingEDGAR ↗
Mar 15, 2018 D
ViewPoint Therapeutics, Inc.
File 021-307759
$0$0$0None listed on this filingEDGAR ↗
Feb 20, 2018 D
Bolt Biotherapeutics, Inc.
File 021-306025
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2016 D
Bolt Biotherapeutics, Inc.
File 021-271607
$0$0$0None listed on this filingEDGAR ↗
Aug 17, 2016 D/A
Tioma Therapeutics, Inc.
File 021-245292
$0$0$0None listed on this filingEDGAR ↗
Sep 25, 2015 D
Corvus Pharmaceuticals, Inc.
File 021-248244
$0$0$0N/A no CRD number reportedEDGAR ↗
Apr 9, 2015 D/A
CARDEAS PHARMA Corp
File 021-196992
$0$0$0None listed on this filingEDGAR ↗
Mar 25, 2015 D/A
Allakos Inc.
File 021-188692
$0$0$0None listed on this filingEDGAR ↗
Apr 17, 2014 D
Rainier Therapeutics, Inc.
File 021-215821
$0$0$0None listed on this filingEDGAR ↗
Sep 27, 2012 D/A
CARDEAS PHARMA Corp
File 021-170976
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 11

Every issuer that named Peter Moldt on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Biotechnology

Avalyn Pharma Inc.

Seattle, WA · Oct 10, 2023
  • Oct 10, 2023 · D · $189,182,622 sold of $189,182,622 · 26 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $189.2M from 46 investors (100% of the $189.2M target) as of the latest filing. Peter is listed as director.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other Health Care

Swift Health Systems Inc.

Irvine, CA · Jul 12, 2019 → Sep 9, 2021 · 2 filings
  • Sep 9, 2021 · D · $101,999,982 sold of $111,999,981 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 12, 2019 · D · $44,999,995 sold of $44,999,995 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $102M from 26 investors (91% of the $112M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Bolt Biotherapeutics, Inc.

Redwood City, CA · Sep 30, 2016 → Jun 7, 2021 · 5 filings
  • Jun 7, 2021 · D · $15,000,000 sold of $15,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 15, 2019 · D · $40,103,799 sold of $40,103,799 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 6, 2018 · D · $13,385,363 sold of $13,385,363 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 20, 2018 · D · $6,000,002 sold of $6,000,002 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 30, 2016 · D · $9,999,998 sold of $15,999,999 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $93.5M from 17 investors (100% of the $15M target) as of the latest filing. Peter is listed as director on 5 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

ESCAPE Bio, Inc.

South San Francisco, CA · Aug 31, 2015 → Sep 28, 2020 · 5 filings
  • Sep 28, 2020 · D · $73,000,000 sold of $73,000,000 · 29 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 29, 2019 · D · $31,073,380 sold of $35,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 11, 2018 · D/A · $63,002,700 sold of $63,002,700 · 31 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 2, 2017 · D/A · $46,002,700 sold of $63,000,000 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 31, 2015 · D · $20,002,700 sold of $55,002,700 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $73M from 32 investors (100% of the $73M target) as of the latest filing. Peter is listed as director on 5 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Aligos Therapeutics, Inc.

South San Francisco, CA · Jan 16, 2020
  • Jan 16, 2020 · D · $85,000,001 sold of $125,000,167 · 38 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $105M from 38 investors (84% of the $125M target) as of the latest filing. Peter is listed as director.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

ViewPoint Therapeutics, Inc.

San Francisco, CA · Mar 15, 2018
  • Mar 15, 2018 · D · $20,935,629 sold of $35,004,729 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20.9M from 17 investors (60% of the $35M target) as of the latest filing. Peter is listed as director.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

Tioma Therapeutics, Inc.

Brisbane, CA · Aug 7, 2015 → Aug 17, 2016 · 2 filings
  • Aug 17, 2016 · D/A · $33,176,948 sold of $86,253,438 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 7, 2015 · D · $8,134,451 sold of $45,000,000 · 10 investors · min. $50,000 · role: Director EDGAR ↗

Raised $33.2M from 12 investors (38% of the $86.3M target) as of the latest filing. Peter is listed as director on 2 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other Health Care

Corvus Pharmaceuticals, Inc.

Burlingame, CA · Sep 25, 2015
  • Sep 25, 2015 · D · $74,999,901 sold of $74,999,901 · 33 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $75M from 33 investors (100% of the $75M target) as of the latest filing. Peter is listed as director.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

CARDEAS PHARMA Corp

Seattle, WA · Dec 30, 2011 → Apr 9, 2015 · 5 filings
  • Apr 9, 2015 · D/A · $37,500,000 sold of $37,500,000 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 23, 2013 · D · $34,000,000 sold of $34,000,000 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 27, 2012 · D/A · $10,527,201 sold of $10,535,985 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 16, 2012 · D/A · $7,535,988 sold of $7,535,988 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 30, 2011 · D · $5,899,995 sold of $7,499,988 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $37.5M from 21 investors (100% of the $37.5M target) as of the latest filing. Peter is listed as director on 5 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Pharmaceuticals

Allakos Inc.

San Carlos, CA · Dec 20, 2012 → Mar 25, 2015 · 3 filings
  • Mar 25, 2015 · D/A · $27,949,545 sold of $47,000,008 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 27, 2014 · D/A · $24,545,452 sold of $41,999,994 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 20, 2012 · D · $9,999,997 sold of $31,999,989 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100.1M from 40 investors (100% of the $47M target) as of the latest filing. Peter is listed as director on 3 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Rainier Therapeutics, Inc.

San Leandro, CA · Apr 17, 2014
  • Apr 17, 2014 · D · $6,000,000 sold of $6,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50M from 10 investors (100% of the $6M target) as of the latest filing. Peter is listed as director.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Peter Moldt — IN, 1 issuer, Oct 12, 2018 → Oct 12, 2018 · no shared issuer

People around Peter 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

Management entity

Bruce Montgomery

Executive Officer, Director, Promoter · 5 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Peter Moldt. Their page shows their other deals.

PT
No photo found yet (own website and image search run after this page is viewed)
Person

Peter A. Thompson

Director · 6 shared filings (2 issuers) · also on 27 other issuers

Peter A. Thompson is on 29 issuers in total — a repeat sponsor. Their page lists every one.

AX
No photo found yet (own website and image search run after this page is viewed)
Person

Asish Xavier

Director · 5 shared filings (1 issuer) · also on 21 other issuers

Asish Xavier is on 22 issuers in total — a repeat sponsor. Their page lists every one.

EE
No photo found yet (own website and image search run after this page is viewed)
Person

Edgar Engleman

Executive Officer, Director · 5 shared filings (1 issuer) · also on 14 other issuers

Edgar Engleman is on 15 issuers in total — a repeat sponsor. Their page lists every one.

MY
No photo found yet (own website and image search run after this page is viewed)
Person

Melissa Yeager

Executive Officer, Promoter · 5 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

KK
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Kinsella

Director · 5 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

MS
No photo found yet (own website and image search run after this page is viewed)
Person

Mahendra Shah

Director · 5 shared filings (1 issuer) · also on 6 other issuers

Mahendra Shah is on 7 issuers in total — a repeat sponsor. Their page lists every one.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John P. McKearn

Director · 5 shared filings (2 issuers) · also on 15 other issuers

John P. McKearn is on 17 issuers in total — a repeat sponsor. Their page lists every one.

RW
No photo found yet (own website and image search run after this page is viewed)
Person

R. Sanders Williams

Director · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Peter Moldt. Their page shows their other deals.

RD
No photo found yet (own website and image search run after this page is viewed)
Person

Robert deGavre

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Peter Moldt. Their page shows their other deals.

GY
No photo found yet (own website and image search run after this page is viewed)
Person

Grant Yonehiro

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Stephen Graham

Executive Officer · 4 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Peter Moldt. Their page shows their other deals.

NT
No photo found yet (own website and image search run after this page is viewed)
Person

Nenad Tomasevic

Executive Officer · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Peter Moldt. Their page shows their other deals.

CB
No photo found yet (own website and image search run after this page is viewed)
Person

Christopher Bebbington

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

AK
No photo found yet (own website and image search run after this page is viewed)
Person

Ashish Khanna

Director · 3 shared filings (1 issuer) · also on 4 other issuers

Ashish Khanna is on 5 issuers in total — a repeat sponsor. Their page lists every one.

PK
No photo found yet (own website and image search run after this page is viewed)
Person

Perry Karsen

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Peter Moldt. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Julie Anne Smith

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

Jill Carroll

Director · 3 shared filings (2 issuers) · also on 3 other issuers

Jill Carroll is on 5 issuers in total — a repeat sponsor. Their page lists every one.

RM
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Miller

Executive Officer, Director · 3 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Peter Moldt. Their page shows their other deals.

LB
No photo found yet (own website and image search run after this page is viewed)
Person

Laura Brass

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Peter Moldt. Their page shows their other deals.

JN
No photo found yet (own website and image search run after this page is viewed)
Person

Jack Nielsen

Director · 2 shared filings (2 issuers) · also on 11 other issuers

Jack Nielsen is on 13 issuers in total — a repeat sponsor. Their page lists every one.

FC
No photo found yet (own website and image search run after this page is viewed)
Person

Farah Champsi

Director · 2 shared filings (1 issuer) · also on 6 other issuers

Farah Champsi is on 7 issuers in total — a repeat sponsor. Their page lists every one.

RK
No photo found yet (own website and image search run after this page is viewed)
Person

Robert W. Karr

Executive Officer, Director · 2 shared filings (1 issuer) · also on 4 other issuers

Robert W. Karr is on 5 issuers in total — a repeat sponsor. Their page lists every one.

LC
No photo found yet (own website and image search run after this page is viewed)
Person

Leon Chen

Executive Officer, Director · 2 shared filings (1 issuer) · also on 9 other issuers

Leon Chen is on 10 issuers in total — a repeat sponsor. Their page lists every one.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Anthony Scullion

Director · 2 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

AD
No photo found yet (own website and image search run after this page is viewed)
Person

Aaron Davidson

Director · 2 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Pamela Manning

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

PP
No photo found yet (own website and image search run after this page is viewed)
Person

Philong Pham

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Peter Moldt. Their page shows their other deals.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Judith Li

Director · 2 shared filings (1 issuer) · also on 5 other issuers

Judith Li is on 6 issuers in total — a repeat sponsor. Their page lists every one.

AR
No photo found yet (own website and image search run after this page is viewed)
Person

Aaron Royston

Director · 2 shared filings (1 issuer) · also on 8 other issuers

Aaron Royston is on 9 issuers in total — a repeat sponsor. Their page lists every one.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Bisgaard

Director · 1 shared filing (1 issuer) · also on 14 other issuers

Peter Bisgaard is on 15 issuers in total — a repeat sponsor. Their page lists every one.

AG
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew C. Goldberg

Director · 1 shared filing (1 issuer) · also on 67 other issuers

Andrew C. Goldberg is on 68 issuers in total — a repeat sponsor. Their page lists every one.

TA
No photo found yet (own website and image search run after this page is viewed)
Person

Tiba Aynechi

Director · 1 shared filing (1 issuer) · also on 10 other issuers

Tiba Aynechi is on 11 issuers in total — a repeat sponsor. Their page lists every one.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

John Donovan

Executive Officer, Director · 1 shared filing (1 issuer) · also on 7 other issuers

John Donovan is on 8 issuers in total — a repeat sponsor. Their page lists every one.

EH
No photo found yet (own website and image search run after this page is viewed)
Person

Ed Hurwitz

Director · 1 shared filing (1 issuer) · also on 5 other issuers

Ed Hurwitz is on 6 issuers in total — a repeat sponsor. Their page lists every one.

KL
No photo found yet (own website and image search run after this page is viewed)
Person

Kathleen LaPorte

Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Peter Moldt. Their page shows their other deals.

LB
No photo found yet (own website and image search run after this page is viewed)
Person

Lawrence Blatt

Executive Officer, Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Peter Moldt. Their page shows their other deals.

LB
No photo found yet (own website and image search run after this page is viewed)
Person

Leonid Beigelman

Executive Officer, Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Peter Moldt. Their page shows their other deals.

PH
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Hirth

Director · 1 shared filing (1 issuer) · also on 7 other issuers

Peter Hirth is on 8 issuers in total — a repeat sponsor. Their page lists every one.

JT
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph L. Turner

Director · 1 shared filing (1 issuer) · also on 5 other issuers

Joseph L. Turner is on 6 issuers in total — a repeat sponsor. Their page lists every one.

The team behind the deals

Same business address

37 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 11 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Peter Moldt by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 11 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Peter Moldt is listed on: none on file. No website or social profile named in Avalyn Pharma Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #115,527 of 374,652 in line (632 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Seattle, WA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Peter Moldt appears on a new Form D, or when a court case or SEC action is matched to them. See plans →